Results 181 to 190 of about 45,933 (222)

Prenatal mTOR-Inhibitor Therapy for Fetal Cardiac Rhabdomyomas: Indications, Treatment Duration and Perinatal Outcomes. [PDF]

J Clin Med
Kyvernitakis I, Schramm K, Wiegand G, Feyerabend B, Baschat AA.   +4 more
europepmc   +1 more source

A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors. [PDF]

Drugs R D
Molina-Cerrillo J, Sierra-Ramirez A, López-Aceituno JL, Méndez-Pertuz M, Alonso-Gordoa T, Linnebacher M, Santoni M, Fernandez-Marcos PJ, Grande E.   +8 more
europepmc   +1 more source

Efficacy and safety of low-dose everolimus and tacrolimus in kidney transplant recipients: A retrospective study. [PDF]

World J Transplant
Pahari DK, Pahari H.
europepmc   +1 more source

Cost savings associated with the adoption of lower-dose everolimus in patients with advanced neuroendocrine tumors. [PDF]

ESMO Gastrointest Oncol
de Almeida GR, Riechelmann RP, Brito AB, Taboada RG, da Silva ALM, Weschenfelder RF, Etges APBS.   +6 more
europepmc   +1 more source

Exceptional response to everolimus in an NF1-deficient recurrent endometrioid adenocarcinoma: a case report. [PDF]

Front Oncol
Machulak M, Zwierzchowska M, Łysak K, Kośmider K, Szklener K, Skórzewska M.   +5 more
europepmc   +1 more source

Everolimus-Involving Immunosuppression Attenuates Renal Interstitial Fibrosis Through Modulation of Mammalian Target of Rapamycin-Related Signal Transduction. [PDF]

Int J Mol Sci
Saito T, Saito M, Yamamoto R, Sagehashi R, Aoyama Y, Mori M, Kajiwara C, Furihata K, Kagaya H, Yagishita H, Fujiyama N, Kashima S, Numakura K, Narita S, Kikuchi M, Miura M, Habuchi T.   +16 more
europepmc   +1 more source

Quantitative correlation of spectroscopic signatures with ligand-protein interactions in anti-cancer drug Afinitor: an integrated experimental-computational study. [PDF]

Sci Rep
Ramana PV, Ram R, Bobbili P, Krishna YR, Panda R, Dominic S, Dakua PK, Kumar S.   +7 more
europepmc   +1 more source

Early neurodevelopmental outcomes in a child with tuberous sclerosis complex treated with everolimus and vigabatrin. [PDF]

BMC Neurol
Wilson SM, Samuels M, Pimentel L, Varnado S, Sartwell C, Mansour R, Pearson D, Northrup H, Koenig MK.   +8 more
europepmc   +1 more source

RETRACTION: Everolimus Plus Ku0063794 Regimen Promotes Anticancer Effects against Hepatocellular Carcinoma Cells through the Paradoxical Inhibition of Autophagy. [PDF]

Cancer Res Treat
Editors of Cancer Research and Treatment.
europepmc   +1 more source

Everolimus-based immunosuppression induces alloreactive regulatory T cell expansion combined with loss of alloreactive effector T cells. [PDF]

Front Immunol
Litjens NHR, Jonker J, Klepper M, Prevoo F, Hesselink DA, Bemelman FJ, Nurmohamed SA, Van Zuilen AD, Berger SP, Sanders JF, Betjes MGH.   +10 more
europepmc   +1 more source